Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + TACE versus TACE alone as adjuvant therapy after radical resection for high-risk hepatocellular carcinoma
ChiCTR2100049661Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Disease-free survival time. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100049661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049661.